DZ2321A1 - Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant. - Google Patents

Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.

Info

Publication number
DZ2321A1
DZ2321A1 DZ970171A DZ970171A DZ2321A1 DZ 2321 A1 DZ2321 A1 DZ 2321A1 DZ 970171 A DZ970171 A DZ 970171A DZ 970171 A DZ970171 A DZ 970171A DZ 2321 A1 DZ2321 A1 DZ 2321A1
Authority
DZ
Algeria
Prior art keywords
arylkylidene
lactams
aralkyl
processes
preparation
Prior art date
Application number
DZ970171A
Other languages
English (en)
Inventor
Harry Ralph Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2321A1 publication Critical patent/DZ2321A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
DZ970171A 1996-09-30 1997-09-29 Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant. DZ2321A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30

Publications (1)

Publication Number Publication Date
DZ2321A1 true DZ2321A1 (fr) 2002-12-28

Family

ID=21835752

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970171A DZ2321A1 (fr) 1996-09-30 1997-09-29 Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.

Country Status (46)

Country Link
US (6) US6380186B1 (fr)
EP (1) EP0929528B1 (fr)
JP (1) JP3121355B2 (fr)
KR (2) KR100323167B1 (fr)
CN (2) CN1093123C (fr)
AP (1) AP769A (fr)
AR (1) AR008861A1 (fr)
AT (1) ATE245630T1 (fr)
AU (1) AU732451B2 (fr)
BG (1) BG64484B1 (fr)
BR (1) BR9713239A (fr)
CA (1) CA2266107C (fr)
CO (1) CO4650135A1 (fr)
CZ (1) CZ295141B6 (fr)
DE (1) DE69723711T2 (fr)
DK (1) DK0929528T3 (fr)
DZ (1) DZ2321A1 (fr)
EA (1) EA002157B1 (fr)
ES (1) ES2202634T3 (fr)
GT (1) GT199700107A (fr)
HK (1) HK1022313A1 (fr)
HN (1) HN1997000135A (fr)
HR (1) HRP970540B1 (fr)
ID (1) ID19833A (fr)
IL (2) IL129045A (fr)
IS (1) IS4985A (fr)
MA (1) MA26443A1 (fr)
MY (1) MY125749A (fr)
NO (1) NO313192B1 (fr)
NZ (1) NZ334215A (fr)
OA (1) OA11002A (fr)
PA (1) PA8439101A1 (fr)
PE (1) PE2799A1 (fr)
PL (1) PL196005B1 (fr)
PT (1) PT929528E (fr)
RS (1) RS49699B (fr)
SA (2) SA05260293B1 (fr)
SI (1) SI0929528T1 (fr)
SK (1) SK284704B6 (fr)
TN (1) TNSN97161A1 (fr)
TR (1) TR199900660T2 (fr)
TW (1) TW491842B (fr)
UA (1) UA56185C2 (fr)
UY (1) UY24730A1 (fr)
WO (1) WO1998014433A1 (fr)
ZA (1) ZA978703B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
DE69919436T2 (de) 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
KR20010086073A (ko) * 1998-12-02 2001-09-07 데이비드 존 우드 ｐ53계 단백질의 배좌 안정성을 회복하기 위한 방법 및조성물
EP1041070B1 (fr) 1999-03-30 2004-09-22 Pfizer Products Inc. Procédé de préparation de thioamides cycliques
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
WO2002078643A2 (fr) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation et action sur des processus cellulaires relatifs aux recepteurs de la famille de la serotonine
EP1746091A1 (fr) * 2001-08-30 2007-01-24 Pfizer Products Inc. Procédure pour la préparation du citrate 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one 2-substitué
ATE332897T1 (de) 2001-08-30 2006-08-15 Pfizer Prod Inc Verfahren zur herstellung von 2-(4-alkyl-1- piperazinyl)-benzaldehyd und -benzylidenyl- derivaten durch nucleophile substitution von 2- fluorobenzaldehyd mit 4-alkyl-1-piperazinen in wasser als lösungsmittel
IL162096A0 (en) * 2001-12-07 2005-11-20 Pfizer Prod Inc Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
EP1469850B1 (fr) 2002-01-02 2013-01-02 Versi Group, LLC Methode de traitement de dysfonctions sexuelles au moyen de composes d'agoniste du recepteur delta opioide
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
JP4977319B2 (ja) * 2002-09-30 2012-07-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
EP1689721B1 (fr) * 2003-11-26 2010-07-14 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
WO2005053701A1 (fr) * 2003-11-26 2005-06-16 Pfizer Products Inc. Association d'agonistes de la dopamine et d'imides et lactames heterocycliques d'aralkyle et d'aralkylidene
EP1697353A2 (fr) * 2003-12-15 2006-09-06 Pfizer Products Incorporated Lactames et imides heterocycliques d'aralkyle et d'aralkylidene
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
EP1737466A1 (fr) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINAISON DE MODULATEURS D'ACIDE GAMMA-AMINOBUTYRIQUE ET D'ANTAGONISTES DU RECEPTEUR 5-HT-1b
EA200601461A1 (ru) * 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. Новые производные бензил(иден)лактама
JP4185154B2 (ja) 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
WO2005113535A2 (fr) * 2004-05-21 2005-12-01 Pfizer Products Inc. Derives pyrazinylmethyle-lactame
WO2005113526A2 (fr) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites de 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
WO2006048727A1 (fr) * 2004-11-02 2006-05-11 Pfizer Products Inc. Ligands de latame/amine piperazinylphenalkyle pour le recepteur 5ht1b
WO2006106416A1 (fr) * 2005-04-08 2006-10-12 Pfizer Products Inc. Pyridil-lactams et leur utilisation comme ligands de recepteurs 5-ht1
WO2007026224A2 (fr) * 2005-08-31 2007-03-08 Pfizer Products Inc. Composition d'antagoniste 5-ht1b pour le traitement de la depression, de l'anxiete et des troubles de la cognition
WO2007026219A2 (fr) * 2005-08-31 2007-03-08 Pfizer Products Inc. Composition d'antagonistes du recepteur 5-ht1b servant au traitement d'etats du systeme nerveux central
WO2007057742A2 (fr) * 2005-11-18 2007-05-24 Pfizer Products Inc. Nouveaux derives de piperazinone
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
MX2010010343A (es) * 2008-03-25 2010-10-15 Univ California Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP3029042A1 (fr) * 2011-10-03 2016-06-08 Euroscreen S.A. Nouvelles n-acyl-5,6,7,(8-méthyl)-tétrahydro-[1,2,4]triazolo[4,3-a]pyrazines chirales en tant qu'antagonistes sélectifs du récepteur nk-3, composition pharmaceutique et procédés pour une utilisation dans les maladies à médiation par le récepteur nk-3
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
DE102013019618A1 (de) * 2013-11-25 2015-05-28 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
CA2099233A1 (fr) * 1992-06-29 1993-12-30 Conrad P. Dorn Antagonistes du recepteur de la tachykinine a base de morpholine et de thiomorpholine
EP0689536B1 (fr) * 1993-03-16 2001-05-23 Pfizer Inc. Derives de naphtalene
US5556841A (en) * 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
EP0767782B1 (fr) * 1994-06-29 2001-10-31 Pfizer Inc. Derives d'aryle et heteroaryle alkoxynaphtalene
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (fr) * 1995-12-14 1997-06-18 Eli Lilly And Company Dérivés de thiomorpholinone pour le traitement de la sclérose en plaques
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides

Also Published As

Publication number Publication date
US20020091117A1 (en) 2002-07-11
BG103297A (en) 1999-11-30
EA002157B1 (ru) 2001-12-24
SA97180449A (ar) 2005-12-03
PT929528E (pt) 2003-12-31
DE69723711D1 (de) 2003-08-28
US6562813B2 (en) 2003-05-13
ID19833A (id) 1998-08-06
CA2266107A1 (fr) 1998-04-09
JP3121355B2 (ja) 2000-12-25
US6472388B2 (en) 2002-10-29
CO4650135A1 (es) 1998-09-03
HRP970540A2 (en) 1998-08-31
PL332629A1 (en) 1999-09-27
SA97180449B1 (ar) 2005-12-21
US20020091119A1 (en) 2002-07-11
AP769A (en) 1999-09-30
CA2266107C (fr) 2002-12-03
ES2202634T3 (es) 2004-04-01
PL196005B1 (pl) 2007-11-30
EP0929528A1 (fr) 1999-07-21
MY125749A (en) 2006-08-30
CZ107199A3 (cs) 2000-05-17
SI0929528T1 (en) 2003-10-31
NO313192B1 (no) 2002-08-26
HK1022313A1 (en) 2000-08-04
KR100323167B1 (ko) 2002-02-04
US6403592B1 (en) 2002-06-11
HN1997000135A (es) 1998-01-28
EA199900242A1 (ru) 1999-08-26
TR199900660T2 (xx) 1999-07-21
KR20000048731A (ko) 2000-07-25
CN1239497C (zh) 2006-02-01
HRP970540B1 (en) 2002-08-31
SK284704B6 (sk) 2005-09-08
KR100346620B1 (ko) 2002-07-26
ZA978703B (en) 1999-03-30
SK41099A3 (en) 2000-09-12
PA8439101A1 (es) 2000-05-24
US20020147194A1 (en) 2002-10-10
CZ295141B6 (cs) 2005-05-18
UA56185C2 (uk) 2003-05-15
IS4985A (is) 1999-02-26
WO1998014433A1 (fr) 1998-04-09
RS49699B (sr) 2007-12-31
CN1093123C (zh) 2002-10-23
DK0929528T3 (da) 2003-10-06
TW491842B (en) 2002-06-21
IL129045A (en) 2005-09-25
AU732451B2 (en) 2001-04-26
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
IL129045A0 (en) 2000-02-17
CN1231661A (zh) 1999-10-13
BG64484B1 (bg) 2005-04-30
US20020091118A1 (en) 2002-07-11
PE2799A1 (es) 1999-02-04
AU3951497A (en) 1998-04-24
BR9713239A (pt) 2000-04-04
YU16899A (sh) 2002-03-18
GT199700107A (es) 1999-03-23
SA05260293B1 (ar) 2006-04-18
DE69723711T2 (de) 2004-02-05
US6627627B2 (en) 2003-09-30
EP0929528B1 (fr) 2003-07-23
ATE245630T1 (de) 2003-08-15
AP9701107A0 (en) 1997-10-31
IL140623A (en) 2005-03-20
NZ334215A (en) 2000-09-29
US20020072519A1 (en) 2002-06-13
UY24730A1 (es) 2000-09-29
US6921760B2 (en) 2005-07-26
CN1329002A (zh) 2002-01-02
US6380186B1 (en) 2002-04-30
AR008861A1 (es) 2000-02-23
NO991525L (no) 1999-05-28
JP2000503679A (ja) 2000-03-28
IL140623A0 (en) 2002-02-10
NO991525D0 (no) 1999-03-29
MA26443A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
DZ2321A1 (fr) Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
MA23866A1 (fr) N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2358A1 (fr) Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2172A1 (fr) Dérivés de triazole utiles on thérapeutique, procédé pour leur préparation et compositions les contenant.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
DZ2360A1 (fr) Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
FR2714848B1 (fr) Microcapsules et procédés pour leur préparation.
DZ2217A1 (fr) Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26438A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
MA26439A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26470A1 (fr) Derives de 1,3,8-triazaspiro (4,5) decane-4-one substitues en position 8, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.